2023-10-19 京éœå€§åŠ
éæ å»åŠç ç©¶ç§æè¡è£äœå¡ãæç¬æºæµ ååææãæµ éé ç§ åææãé«åå€§èŒ æšªæµåžç«å€§åŠç¹ä»»åææãå·åŽãã åææãã®å ±åç ç©¶ã°ã«ãŒãã¯ãβ1,4-ã¬ã©ã¯ããŒã¹è»¢ç§»é µçŽ -3(B4GALT3) ã®æ¬ æããŠã¹ãé«å ç«åæ§è «çã®å¢æ®ãæå¶ããããšãçºèŠããŸããããã®çºèŠã¯ãããå ç«çæ³ã«å¿çšã§ããããšãæåŸ ãããŸãã
B4GALT3ã¯ãå€ãã®è «çã«ãããŠãã®åšèŸºã®æ£åžžçµç¹ããé«ãçºçŸã瀺ããç¥çµèœè «ãåå®®é žãããèè±ãããªã©ã®ããã®èšåºäºåŸãšé¢é£ããŠããŸãããããããã埮å°ç°å¢(TIME)ã§ã®B4GALT3ã®å ·äœçãªåœ¹å²ã¯ãŸã äžæã§ãããæ¬ç ç©¶ã§ãCrispr/Cas9ã·ã¹ãã ã«ããäœè£œããB4GALT3ããã¯ã¢ãŠã(KO)ããŠã¹ãçšããŠå®éšãè¡ã£ãçµæãB4GALT3 KOããŠã¹ã§ã¯ãå ç«åæ§ã®åŒ·ãè «ç现èã®å¢æ®ãæå¶ãããè «çã«æµžæœ€ããCD8+T现èã®æ°ãææã«å¢å ããããšãããããŸããã
ããã«ãB4GALT3ã®æ¬ æã¯ãCD8+T现è衚é¢ã®ã€ã³ãã°ãªã³Î±Lã®Nåç³é修食ãå€åãããããšã瀺ãããŸããããã®ç ç©¶ã¯ãå ç«çްèã®è¡šé¢ã¿ã³ãã¯è³ªã®ç³é修食ãæäœããããšã«ãããããå ç«çæ³ã®æ°ããªã¢ãããŒããšããŠã®å¯èœæ§ã瀺ããŠããŸãã
æ¬ç ç©¶ææã¯ã2023幎10æ9æ¥ã«ãåœéåŠè¡èªãFrontiers in Immunologyãã«ãªã³ã©ã€ã³æ²èŒãããŸããã

ç ç©¶è ã®ã³ã¡ã³ã
ããã®ç ç©¶ãéããŠãç³éã®åœ¹å²ãšãã埮å°ç°å¢ã«ããããã®åœ±é¿ã«ã€ããŠã®æ°ããç¥èŠãåŸãããšãã§ããŸã ããç³éã®éèŠæ§ãšããæ²»çãžã®æ°ããã¢ãããŒãã®å¯èœæ§ãæããã«ãªããŸãããç³éã®ç ç©¶ã¯ãæªæ¥ã®å»çã«ãããŠæ°ããçªç Žå£ãéãããšãæåŸ ãããŸããã
詳ããç ç©¶å 容ã«ã€ããŠ
ç ç©¶è æ å ±
ç ç©¶è
å:æç¬ æºæµ
ç ç©¶è
å:æµ
é é
ç§

